Assessment of rheumatologic tolerability of letrozole in postmenopausal patients with hormone receptor positive breast cancer having discontinued anastrozole adjuvant treatment due to musculoskeletal disorders

Trial Profile

Assessment of rheumatologic tolerability of letrozole in postmenopausal patients with hormone receptor positive breast cancer having discontinued anastrozole adjuvant treatment due to musculoskeletal disorders

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Letrozole (Primary)
  • Indications Breast cancer
  • Focus Adverse reactions
  • Sponsors Novartis
  • Most Recent Events

    • 01 Oct 2008 Actual end date (Jan 2008) added as reported by ClinicalTrials.gov.
    • 01 Oct 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top